An AI-based clinical data solution to assist in the initial prevention and detection of high-burden conditions, Medial EarlySign, has seen its ColonFlag implemented by Barts Health to care and prioritise for patients at considerable risk for developing colon cancer.
To help physicians perform proactive and targeted interventions for optimal care, EarlySign’s AI model assesses current routine clinical data to prioritise and foretell people at high risk of developing colon cancer.
“Medial EarlySign has seen its ColonFlag implemented by Barts Health.“
Consultant haemato-oncologist, Barts Health and lead for molecular pathology, Professor Finbarr Cotter, stated: “The COVID-19 pandemic has created a challenging situation in which many patients are still awaiting routine treatments and screenings, including for colon cancer, which is the 4th most common cancer in the UK. Integrating EarlySign’s platform into our workstream has helped us to successfully identify patients who would most benefit from screening and intervention, supporting our goal of delivering timely and personalised care to our patients. We are now exploring opportunities to extend our use of EarlySign’s technology to other health areas.”
EarlySign’s chief commercial officer EU and COO, Itai Katzir, stated: "EarlySign’s Back to Care initiative is designed to handle the backlog of postponed treatments due to the coronavirus pandemic and we are excited to support Barts Health in providing personal and timely treatment for people at high risk of developing serious conditions. Barts Health is one of the world’s leading health systems and we are proud to count them among our growing international customer base, joining prestigious organisations across the US and Europe.”